Drugs Developed for Subcutaneous Injection Benefiting from the Trend to Patient Self-Administration

(Amherst, NH) – As healthcare markets continue to evolve, drug developers and their supply chain partners are attempting to keep pace by addressing economic, market and therapeutic factors that increasingly revolve around how, when and where drugs are administered. This evolution is being driven by new and exciting options for patient care in the form of powerful drug therapies for treating diseases with improved outcomes and for treating diseases for which an effective treatment did not previously exist.

Beyond oncology – where therapeutic drugs continue to be supplied for administration via infusion – the majority of new non-oral drugs are being formulated for subcutaneous injection. Many of these drugs are indicated for chronic conditions, which because of the continuous need for dosing over time benefit significantly when patients can self-administer their medication.

Importantly, as technology has evolved devices for self-administering drugs subcutaneously can now be divided into two major groups: (1) handheld devices, and (2) wearable devices. The first group includes syringes, pen injectors and autoinjectors. While these devices are familiar to most patients, their sophistication and usability continue to improve. Wearable insulin delivery devices were the first established device class in the second group. These pump-enabled devices now compete with smaller, integrated devices known as patch pumps.

Major therapeutic markets for self-administered subcutaneous injectables include autoimmune diseases, hormone replacement, metabolic diseases such as diabetes and osteoporosis, and blood thinners. And while oncology drugs continue to be developed for infusion in a healthcare setting, the approval of Roche’s Herceptin, an antibody indicated for treating HER2-positive breast cancer, as a subcutaneous formulation (Herceptin SC) in Europe last year is a glimpse into the future. Herceptin SC is enabled by recombinant technology supplied by Halozyme.

The evolving subcutaneous self-administration landscape is detailed in a new and comprehensive report researched and written by Greystone Research Associates. Subcutaneous Self-Administration Markets to 2022 analyzes the global market for injectable drugs designed for subcutaneous self-administration. The report analyzes demand drivers, development factors, market considerations, and strategic and economic factors, and provides profiles of market sector participants.

More information is available at http://www.greystoneassociates.org

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

This release was published on openPR.